The role of chemokines in breast cancer pathology and its possible use as therapeutic targets

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Palacios Arreola, M Isabel ^a   Nava Castro, Karen E ^a,b   Castro, Julieta I ^b   García Zepeda, Eduardo ^a   Carrero, Julio C ^a   Morales Montor, Jorge ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; HUMAN; METASTASIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOKINES; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84928719182     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/849720     Document Type: Review

References (56)

1. M. Locati, K. Otero, T. Schioppa, et al., "The chemokine system: Tuning and shaping by regulation of receptor expression and coupling in polarized responses, " Allergy, vol. 57, no. 11, pp. 972-982, 2002.
2. A. Rot and U. H. von Andrian, "Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells, " Annual Review of Immunology, vol. 22, pp. 891-928, 2004.
3. S. J. Allen, S. E. Crown, and T. M. Handel, "Chemokine: receptor structure, interactions, and antagonism, " Annual Review of Immunology, vol. 25, pp. 787-820, 2007.
4. J. Ferlay, I. Soerjomataram, M. Ervik, et al., LOBOCAN2012 v1. 0: Cancer Incidence and Mortality Worldwide: IARC CancerCase No. 11, 2013.
5. S. B. Edge and C. C. Compton, "The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, " Annals of Surgical Oncology, vol. 17, no. 6, pp. 1471-1474, 2010.
6. S. M. Burnet, "Cancer-a biological approach, " British Medical Journal, vol. 1, no. 5023, pp. 841-847, 1957.
7. M. J. Smyth, G. P. Dunn, and R. D. Schreiber, "Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity, " Advances in Immunology, vol. 90, pp. 1-50, 2006.
8. G. P. Dunn, L. J. Old, and R. D. Schreiber, "The immunobiology of cancer immunosurveillance and immunoediting, " Immunity, vol. 21, no. 2, pp. 137-148, 2004.
9. S. Ali and G. Lazennec, "Chemokines: novel targets for breast cancer metastasis, " Cancer and Metastasis Reviews, vol. 26, no. 3-4, pp. 401-420, 2007.
10. S. L. Deshmane, S. Kremlev, S. Amini, and B. E. Sawaya, "Monocyte chemoattractant protein-1 (MCP-1): an overview, " Journal of Interferon and Cytokine Research, vol. 29, no. 6, pp. 313-326, 2009.
11. G. Soria and A. Ben-Baruch, "The inflammatory chemokines CCL2 and CCL5 in breast cancer, " Cancer Letters, vol. 267, no. 2, pp. 271-285, 2008.
12. A. Ben-Baruch, "The multifaceted roles of chemokines in malignancy, " Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 357-371, 2006.
13. A. Tsuyada, A. Chow, J. Wu, et al., "CCL2 mediates crosstalk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells, " Cancer Research, vol. 72, no. 11, pp. 2768-2779, 2012.
14. S. Marsigliante, C. Vetrugno, and A. Muscella, "CCL20 induces migration and proliferation on breast epithelial cells, " Journal of Cellular Physiology, vol. 228, no. 9, pp. 1873-1883, 2013.
15. N. Shao, L.-H. Chen, R.-Y. Ye, Y. Lin, and S.-M. Wang, "The depletion of Interleukin-8 causes cell cycle arrest and increases the efficacy of docetaxel in breast cancer cells, " Biochemical and Biophysical Research Communications, vol. 431, no. 3, pp. 535-541, 2013.
16. J. K. Singh, G. Farnie, N. J. Bundred, et al., "Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms, " Clinical Cancer Research, vol. 19, no. 3, pp. 643-656, 2013.
17. L. V. Rhodes, S. P. Short, N. F. Neel, et al., "Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer, " Cancer Research, vol. 71, pp. 603-613, 2011.
18. X.-L. Gu, Z.-L. Ou, F.-J. Lin, et al., "Expression of CXCL14 and its anticancer role in breast cancer, " Breast Cancer Research and Treatment, vol. 135, no. 3, pp. 725-735, 2012.
19. H. Fujimoto, T. Sangai, G. Ishii, et al., "Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression, " International Journal of Cancer, vol. 125, no. 6, pp. 1276-1284, 2009.
20. T. Ueno, M. Toi, H. Saji, et al., "Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer, " Clinical Cancer Research, vol. 6, no. 8, pp. 3282-3289, 2000.
21. S. C. Robinson, K. A. Scott, J. L. Wilson, R. G. Thompson, A. E. I. Proudfoot, and F. R. Balkwill, "Achemokine receptor antagonist inhibits experimental breast tumor growth, " Cancer Research, vol. 63, no. 23, pp. 8360-8365, 2003.
22. E. P. Adler, C. A. Lemken, N. S. Katchen, and R. A. Kurt, "A dual role for tumor-derived chemokine RANTES (CCL5), " Immunology Letters, vol. 90, no. 2-3, pp. 187-194, 2003.
23. L. F. Neville, G. Mathiak, and O. Bagasra, "The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily, " Cytokine and Growth Factor Reviews, vol. 8, no. 3, pp. 207-219, 1997.
24. J. M. Farber, "Mig and IP-10: CXC chemokines that target lymphocytes, " Journal of Leukocyte Biology, vol. 61, no. 3, pp. 246-257, 1997.
25. R. M. Strieter, J. A. Belperio, R. J. Phillips, and M. P. Keane, "CXC chemokines in angiogenesis of cancer, " Seminars in Cancer Biology, vol. 14, no. 3, pp. 195-200, 2004.
26. R. M. Strieter, M. D. Burdick, J. Mestas, B. Gomperts, M. P. Keane, and J. A. Belperio, "Cancer CXC chemokine networks and tumour angiogenesis, " European Journal of Cancer, vol. 42, no. 6, pp. 768-778, 2006.
27. S. A. Williams, Y. Harata-Lee, I. Comerford, R. L. Anderson, M. J. Smyth, and S. R. McColl, "Multiple functions of CXCL12 in a syngeneic model of breast cancer, " Molecular Cancer, vol. 9, article 250, 2010.
28. G. E. White and D. R. Greaves, "Fractalkine: a survivors guide-chemokines as antiapoptotic mediators, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 3, pp. 589-594, 2012.
29. M. H. Park, J. S. Lee, and J. H. Yoon, "High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma, " Journal of Surgical Oncology, vol. 106, no. 4, pp. 386-392, 2012.
30. Y. Mizukami, K. Kono, Y. Kawaguchi, et al., "CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer, " International Journal of Cancer, vol. 122, no. 10, pp. 2286-2293, 2008.
31. T. Maruyama, K. Kono, S. Izawa, et al., "CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma, " Diseases of the Esophagus, vol. 23, no. 5, pp. 422-429, 2010.
32. T. J. Curiel, G. Coukos, L. Zou, et al., "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, " Nature Medicine, vol. 10, no. 9, pp. 942-949, 2004.
33. J. Faget, C. Biota, T. Bachelot, et al., "Early detection of tumor cells by innate immune cells leads to T reg recruitment through CCL22 production by tumor cells, " Cancer Research, vol. 71, no. 19, pp. 6143-6152, 2011.
34. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
35. K. Haim, P. Weitzenfeld, T. Meshel, and A. Ben-Baruch, "Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells, " Neoplasia, vol. 13, no. 3, pp. 230-243, 2011.
36. W. Zhuo, L. Jia, N. Song, et al., "TheCXCL12-CXCR4chemokine pathway: a novel axis regulates lymphangiogenesis, " Clinical Cancer Research, vol. 18, no. 19, pp. 5387-5398, 2012.
37. M. Yu, R. Berk, and M. A. Kosir, "CXCL7-mediated stimulation of lymphangiogenic factors VEGF-C, VEGF-D in human breast cancer cells, " Journal of Oncology, vol. 2010, Article ID 939407, 10 pages, 2010.
38. Z. Liang, W. Zhan, A. Zhu, et al., "Development of a unique small molecule modulator of cxcr4, " PLoS ONE, vol. 7, no. 4, Article ID e34038, 2012.
39. M. Z. Dewan, S. Ahmed, Y. Iwasaki, K. Ohba, M. Toi, and N. Yamamoto, "Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer, " Biomedicine and Pharmacotherapy, vol. 60, no. 6, pp. 273-276, 2006.
40. A. Müller, B. Homey, H. Soto, et al., "Involvement of chemokine receptors in breast cancer metastasis, " Nature, vol. 410, no. 6824, pp. 50-56, 2001.
41. D. Mukherjee and J. Zhao, "The Role of chemokine receptor CXCR4 in breast cancer metastasis, "American Journal of Cancer Research, vol. 3, pp. 46-57, 2013.
42. M. Kucia, R. Reca, K. Miekus, et al., "Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis, " Stem Cells, vol. 23, no. 7, pp. 879-894, 2005.
43. C. V. Hinton, S. Avraham, and H. K. Avraham, "Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain, " Clinical and Experimental Metastasis, vol. 27, no. 2, pp. 97-105, 2010.
44. H.-W. Chen, C.-W. Du, X.-L. Wei, U.-S. Khoo, and G.-J. Zhang, "Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer, " Current Molecular Medicine, vol. 13, no. 3, pp. 410-416, 2013.
45. A. P. Molloy, F. T. Martin, R. M. Dwyer, et al., "Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells, " International Journal of Cancer, vol. 124, no. 2, pp. 326-332, 2009.
46. W. L. Jamieson-Gladney, Y. Zhang, A. M. Fong, O. Meucci, and A. Fatatis, "The chemokine receptor CX3CR1 is directly involved in the arrest of breast cancer cells to the skeleton, " Breast Cancer Research, vol. 13, no. 5, article R91, 2011.
47. L. Hernandez, M. A. O. Magalhaes, S. J. Coniglio, J. S. Condeelis, and J. E. Segall, "Opposing roles ofCXCR4 andCXCR7 in breast cancer metastasis, " Breast Cancer Research, vol. 13, no. 6, article R128, 2011.
48. J. Chen, Y. Yao, C. Gong, et al., "CCL18 from Tumor-AssociatedMacrophages Promotes BreastCancerMetastasis via PITPNM3, " Cancer Cell, vol. 19, no. 4, pp. 541-555, 2011.
49. C. Johnson-Holiday, R. Singh, E. L. Johnson, W. E. Grizzle, J. W. Lillard Jr., and S. Singh, "CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion, " World Journal of Surgical Oncology, vol. 9, article 43, 2011.
50. S. Acharyya, T. Oskarsson, S. Vanharanta, et al., "A CXCL1 paracrine network links cancer chemoresistance and metastasis, " Cell, vol. 150, no. 1, pp. 165-178, 2012.
51. M. Velasco-Velázquez, X. Jiao, M. De La Fuente, et al., "CCR5 antagonist blocks metastasis of basal breast cancer cells, " Cancer Research, vol. 72, no. 15, pp. 3839-3850, 2012.
52. C. Ginestier, S. Liu, M. E. Diebel, et al., "CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts, " Journal of Clinical Investigation, vol. 120, no. 2, pp. 485-497, 2010.
53. H. Tamamura, A. Hori, N. Kanzaki, et al., "T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer, " FEBS Letters, vol. 550, no. 1-3, pp. 79-83, 2003.
54. T. Nguyen-Hoai, G. Baldenhofer, M. S. Ahmed, et al., "CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model, " Journal of Gene Medicine, vol. 14, no. 2, pp. 128-137, 2012.
55. T. Nguyen-Hoai, G. Baldenhofer, M. S. Sayed Ahmed, et al., "CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model, " Cancer Gene Therapy, vol. 19, no. 1, pp. 69-76, 2012.
56. M. Gil, M. Seshadri, M. P. Komorowski, S. I. Abrams, and D. Kozbor, "Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 14, pp. E1291-E1300, 2013.